Phase 2 randomized
Showing 1 - 25 of >10,000
Cancer, MDD Trial in Rockville (Psilocybin, Placebo)
Recruiting
- Cancer
- Major Depressive Disorder
- Psilocybin
- Placebo
-
Rockville, MarylandSunstone Medical, PC
Jul 7, 2023
Healthy Participants Trial (mPnC candidate, mPnC control)
Not yet recruiting
- Healthy Participants
- mPnC candidate
- mPnC control
- (no location specified)
Oct 30, 2023
Diabetic Macular Edema, Diabetic Retinopathy Trial (4D-150 IVT, Aflibercept IVT)
Not yet recruiting
- Diabetic Macular Edema
- Diabetic Retinopathy
- 4D-150 IVT
- Aflibercept IVT
- (no location specified)
Jun 26, 2023
Eosinophilic Esophagitis Trial (barzolvolimab, Matching Placebo)
Not yet recruiting
- Eosinophilic Esophagitis
- barzolvolimab
- Matching Placebo
- (no location specified)
Mar 7, 2023
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder) Trial (MBS-COV, Placebo)
Not yet recruiting
- Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
- MBS-COV
- Placebo
- (no location specified)
Jul 11, 2023
Hyperphosphatemia Patients on Hemodialysis Trial in Tokyo (TS-172 10mg bid, TS-172 30mg bid, TS-172 60mg bid)
Not yet recruiting
- Hyperphosphatemia Patients on Hemodialysis
- TS-172 10mg bid
- +4 more
-
Tokyo, JapanTaisho Pharmaceutical Co., Ltd selected site
Jan 23, 2023
Marburg Virus Disease Trial in Siaya, Kampala (cAd3-Marburg vaccine, Placebo)
Not yet recruiting
- Marburg Virus Disease
- cAd3-Marburg vaccine
- Placebo
-
Siaya, Kenya
- +1 more
Apr 17, 2023
Lassa Fever Trial (Day 1 Lower Dose (2×106 pfu), Day 1 Higher Dose (1×107 pfu), Placebo)
Not yet recruiting
- Lassa Fever
- Day 1 Lower Dose (2×106 pfu)
- +2 more
- (no location specified)
May 19, 2023
Opioid Use Disorder Trial in Salt Lake City (MORE-VR, Treatment as Usual)
Not yet recruiting
- Opioid Use Disorder
- MORE-VR
- Treatment as Usual
-
Salt Lake City, UtahUniversity of Utah
Sep 3, 2023
Androgenetic Alopecia Trial in Gyeonggi-do (CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3)
Recruiting
- Androgenetic Alopecia
- CKD-498 dose#1
- +5 more
-
Gyeonggi-do, Korea, Republic ofSeoul National University Bundang Hospital
Jan 10, 2023
Atopic Dermatitis Trial in Shenyang, Jinan (1.5% QLM3003, 2% QLM3003, Vehicle (Placebo))
Not yet recruiting
- Atopic Dermatitis
- 1.5% QLM3003
- +2 more
-
Shenyang, Liaoning, China
- +1 more
Sep 21, 2023
Dermatomyositis, Polymyositis, Idiopathic Inflammatory Myopathies Trial (Froniglutide, Placebo)
Not yet recruiting
- Dermatomyositis
- +2 more
- Froniglutide
- Placebo
- (no location specified)
Apr 16, 2023
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)
Not yet recruiting
- Breast Cancer
- +3 more
- (no location specified)
Aug 4, 2023
Ankylosing Spondylitis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, Placebo)
Completed
- Ankylosing Spondylitis
- LNK01001 Dose A
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
Oct 10, 2023
Cancer Trial in Halifax (CancerPEP)
Not yet recruiting
- Cancer
- CancerPEP
-
Halifax, Nova Scotia, CanadaQEII Health Sciences Centre
Aug 18, 2022
Idiopathic Inflammatory Myositis Trial (Daxdilimab, Placebo)
Not yet recruiting
- Idiopathic Inflammatory Myositis
- Daxdilimab
- Placebo
- (no location specified)
Dec 20, 2022
Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)
Not yet recruiting
- Head and Neck Neoplasms
- TransCon TLR7/8 Agonist
- +2 more
- (no location specified)
Aug 4, 2023